Agios Pharma (AGIO) Phase 1 AG-120 Data Shows Clinical Activity in AML
Tweet Send to a Friend
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced the first reported safety and clinical activity for AG-120 from the ongoing Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
